{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T01:18:40Z","timestamp":1707873520495},"reference-count":36,"publisher":"Pan American Health Organization","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,12]]},"abstract":"<sec>\n<title>Objetivo.<\/title>\n<p>Analizar la existencia y actualizaci\u00f3n de las listas de medicamentos nacionales (LMN) y gu\u00edas de pr\u00e1ctica cl\u00ednica (GPC) para el tratamiento de la diabetes en Am\u00e9rica Latina y el Caribe (ALC). Comparar los f\u00e1rmacos incluidos en las listas y gu\u00edas de cada pa\u00eds, entre s\u00ed y con los de la Organizaci\u00f3n Mundial de la Salud (OMS).<\/p>\n<\/sec>\n<sec>\n<title>M\u00e9todos.<\/title>\n<p>Estudio de corte transversal. Se identificaron las LMN y GPC para diabetes en los sitios web de la Organizaci\u00f3n Panamericana de la Salud y de las autoridades sanitarias nacionales. Se relevaron los f\u00e1rmacos y se analizaron por grupo farmacol\u00f3gico seg\u00fan el cuarto nivel de la nomenclatura ATC. Se utiliz\u00f3 el puntaje F1 para evaluar la proximidad de las LMN con la lista modelo de medicamentos esenciales (LMME) de la OMS.<\/p>\n<\/sec>\n<sec>\n<title>Resultados.<\/title>\n<p>Del total de pa\u00edses, 87,2% cuentan con LMN, y 91% con GPC (78% y 45% actualizadas en los \u00faltimos 5 a\u00f1os, respectivamente). En comparaci\u00f3n con los 6 grupos de hipoglucemiantes de la LMME, las LMN ten\u00edan una mediana (rango) de 6 (4-13) y un puntaje F1 de 0,80; esto indica una consonancia adecuada. Las GPC ten\u00edan una mediana (rango) de 12 (1-12) hipoglucemiantes frente a los 8 de las gu\u00edas de la OMS. Las GPC tuvieron una mediana de 15 f\u00e1rmacos m\u00e1s que las respectivas LMN.<\/p>\n<\/sec>\n<sec>\n<title>Conclusiones.<\/title>\n<p>Si bien la mayor\u00eda de los pa\u00edses de ALC cuentan con LMN y GPC para diabetes, la falta de concordancia entre ellas limita su eficacia. Es necesario alinear los procesos y criterios de elaboraci\u00f3n de estas dos herramientas de la pol\u00edtica de medicamentos.<\/p>\n<\/sec>","DOI":"10.26633\/rpsp.2024.3","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T17:22:40Z","timestamp":1707844960000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Concordancia entre las listas de medicamentos esenciales y las gu\u00edas para diabetes en Am\u00e9rica Latina y el Caribe"],"prefix":"10.26633","volume":"48","author":[{"given":"Mart\u00edn Alejandro","family":"Urtasun","sequence":"first","affiliation":[{"name":"Centro de Informaci\u00f3n de Medicamentos, Fundaci\u00f3n FEMEBA, La Plata, Argentina."},{"name":"murtasun@femeba.org.ar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian","family":"Dorati","sequence":"additional","affiliation":[{"name":"Centro Universitario de Farmacolog\u00eda, Facultad de Ciencias M\u00e9dicas, Universidad Nacional de La Plata, Centro Colaborador de la OPS\/OMS, La Plata, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart\u00edn","family":"Ca\u00f1\u00e1s","sequence":"additional","affiliation":[{"name":"Centro de Informaci\u00f3n de Medicamentos, Fundaci\u00f3n FEMEBA, La Plata, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Silvina","family":"Bruzzone","sequence":"additional","affiliation":[{"name":"Centro Universitario de Farmacolog\u00eda, Facultad de Ciencias M\u00e9dicas, Universidad Nacional de La Plata, Centro Colaborador de la OPS\/OMS, La Plata, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo H.","family":"Mar\u00edn","sequence":"additional","affiliation":[{"name":"Centro Universitario de Farmacolog\u00eda, Facultad de Ciencias M\u00e9dicas, Universidad Nacional de La Plata, Centro Colaborador de la OPS\/OMS, La Plata, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasim","family":"Iusef Venturini","sequence":"additional","affiliation":[{"name":"Centro Universitario de Farmacolog\u00eda, Facultad de Ciencias M\u00e9dicas, Universidad Nacional de La Plata, Centro Colaborador de la OPS\/OMS, La Plata, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perla","family":"Mordujovich Buschiazzo","sequence":"additional","affiliation":[{"name":"Centro Universitario de Farmacolog\u00eda, Facultad de Ciencias M\u00e9dicas, Universidad Nacional de La Plata, Centro Colaborador de la OPS\/OMS, La Plata, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11167","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020;10(1):14790.","DOI":"10.1038\/s41598-020-71908-9"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Organizaci\u00f3n Panamericana de la Salud. Panorama de la diabetes en la Regi\u00f3n de las Am\u00e9ricas. Washington, D.C.: OPS; 2023. Disponible en: https:\/\/doi.org\/10.37774\/9789275326336.","DOI":"10.37774\/9789275326336"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Kaselitz E, Rana GK, Heisler M. Public policies and interventions for diabetes in Latin America: a scoping review. Curr Diab Rep. 2017;17(8):65.","DOI":"10.1007\/s11892-017-0888-x"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Fralick M, Jenkins AJ, Khunti K, Mbanya JC, Mohan V, Schmidt MI. Global accessibility of therapeutics for diabetes mellitus. Nat Rev Endocrinol. 2022;18(4):199-204. Doi: 10.1038\/s41574-021-00621-y.","DOI":"10.1038\/s41574-021-00621-y"},{"key":"ref5","unstructured":"Organizaci\u00f3n Mundial de la Salud. Selecci\u00f3n de medicamentos esenciales. Ginebra: OMS; 2002. Disponible en: https:\/\/apps.who.int\/iris\/handle\/10665\/67377."},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Sanabria AJ, Rigau D, Rotaeche R, Selva A, Marzo-Castillejo M, Alonso-Coello P. Sistema GRADE: metodolog\u00eda para la realizaci\u00f3n de recomendaciones para la pr\u00e1ctica cl\u00ednica. Aten Primaria. 2015;47(1):48-55.","DOI":"10.1016\/j.aprim.2013.12.013"},{"key":"ref7","unstructured":"FoliaDOC. Metformina en el tratamiento de la diabetes mellitus tipo 2. Suplemento especial noviembre 2016. Fundaci\u00f3n Femeba; 2016. Disponible en: https:\/\/bit.ly\/49xlKLG."},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Piggott T, Moja L, Akl EA, Lavis JN, Cooke G, Kredo T, et al. Decision criteria for selecting essential medicines and their connection to guidelines: an interpretive descriptive qualitative interview study. J Clin Epidemiol. 2023;154:146-155.","DOI":"10.1016\/j.jclinepi.2022.12.007"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Mardetko, N., Nabergoj Makovec, U., Locatelli, I. et al. Uptake of new antidiabetic medicines in 11 European countries. BMC Endocr Disord 2021;21:127. Disponible en: https:\/\/doi.org\/10.1186\/s12902-021-00798-3.","DOI":"10.1186\/s12902-021-00798-3"},{"key":"ref10","unstructured":"Organizaci\u00f3n Panamericana de la Salud. Pa\u00edses y centros colaboradores. Washington D. C.: OPS. Disponible en: https:\/\/www.paho.org\/es\/paises-centros."},{"key":"ref11","unstructured":"Organizaci\u00f3n Panamericana de la Salud. Listas anotadas de medicamentos y dispositivos. Washington D. C.: OPS. Disponible en: https:\/\/medlist.paho.org\/es\/."},{"key":"ref12","unstructured":"Organizaci\u00f3n Mundial de la Salud. The selection and use of essential medicines 2023: Executive summary of the report of the 24th WHO Expert Committee on the Selection and Use of Essential Medicines, 24-28 April 2023. Ginebra: OMS; 2023. Disponible en: WHO-MHP-HPS-EML-2023.01-eng.pdf."},{"key":"ref13","unstructured":"Organizaci\u00f3n Mundial de la Salud. Guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus. Ginebra: OMS; 2018."},{"key":"ref14","unstructured":"Organizaci\u00f3n Panamericana de la Salud. Diagn\u00f3stico y manejo de la diabetes de tipo 2 (HEARTS-D). Washington, D.C.: OPS; 2020."},{"key":"ref15","unstructured":"Organizaci\u00f3n Mundial de la Salud. ATC\/DDD Index 2023. WHO Collaborating centre for drug statistics methodology. Ginebra: OMS. Disponible en: https:\/\/www.whocc.no\/atc_ddd_index\/."},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Piggott T, Nowak A, Brignardello-Petersen R, Cooke GS, Huttner B, Sch\u00fcnemann HJ, et al. Global status of essential medicine selection: a systematic comparison of national essential medicine lists with recommendations by WHO. BMJ Open. 2022;12(2):e053349.","DOI":"10.1136\/bmjopen-2021-053349"},{"key":"ref17","unstructured":"Banco Mundial. PIB per c\u00e1pita. Washington D.C.: Banco Mundial. Disponible en: https:\/\/datos.bancomundial.org\/indicator\/NY.GDP.PCAP.CD."},{"key":"ref18","unstructured":"International Diabetes Federation. IDF Diabetes Atlas 2021: 10\u00b0 ed. Disponible en: www.diabetesatlas.org."},{"key":"ref19","unstructured":"StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP."},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, G\u00f8tzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007;18(6):805-35. Doi: 10.1097\/EDE.0b013e3181577511.","DOI":"10.1097\/EDE.0b013e3181577511"},{"key":"ref21","unstructured":"Divisi\u00f3n de Poblaci\u00f3n de las Naciones Unidas. 27\u00b0 ed (en l\u00ednea). Nueva Yor: Departamento de Asuntos Econ\u00f3micos y Sociales de las Naciones Unidas. Disponible en: https:\/\/population.un.org\/wpp\/."},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Rowlands A, Acosta-Gualandri A, Guevara-Aguirre J, Chanoine JP. WHO and national lists of essential medicines in Mexico, Central and South America, and the Caribbean: are they adequate to promote paediatric endocrinology and diabetes care? BMJ GlobHealth. 2016;1(3):e000114.","DOI":"10.1136\/bmjgh-2016-000114"},{"key":"ref23","unstructured":"Ca\u00f1\u00e1s M, Urtasun MA. Nuevos hipoglucemiantes en los listados de medicamentos esenciales de los pa\u00edses de Latinoam\u00e9rica. Red CIMLAC Informa. 2019;IV(7). Disponible en: https:\/\/bit.ly\/3QugjV6."},{"key":"ref24","unstructured":"Ca\u00f1\u00e1s M, Carlson S, Dorati C, Giulietti M, Mordujovich- Buschiazzo P. Evaluaci\u00f3n comparativa de los medicamentos incluidos en gu\u00edas de tratamiento y en la 15\u00aa Lista de medicamentos esenciales de la OMS. Centro Universitario de Farmacolog\u00eda (CUFAR), Facultad de Medicina, Universidad Nacional de La Plata. Informe t\u00e9cnico, noviembre 2008. Disponible en: https:\/\/bit.ly\/40RwmkN."},{"key":"ref25","unstructured":"Organizaci\u00f3n Mundial de la Salud. The selection and use of essential medicines: report of the WHO Expert Committee, 2017. Ginebra: OMS; 2017. Disponible en: https:\/\/apps.who.int\/iris\/handle\/10665\/259481."},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Joshua IB, Passmore PR, Sunderland BV. An evaluation of the essential medicines list, standard treatment guidelines and prescribing restrictions, as an integrated strategy to enhance quality, efficacy, and safety of and improve access to essential medicines in Papua New Guinea. Health Policy Plan. 2016;31(4):538-46.","DOI":"10.1093\/heapol\/czv083"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Cheng L, Li C, Zhang X, Chen Y and Yan J. The consistency between the Chinese essential medicines list and treatment guidelines\u2014taking oncology medicines as an example. Front Public Health. 2022;10:943994.","DOI":"10.3389\/fpubh.2022.943994"},{"key":"ref28","unstructured":"European Medical Agency. Guideline on clinical development of fixed combination medicinal products. Committee for Human Medicinal Products (CHMP); 2017. Disponible en: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-development-fixed-combination-medicinal-products-revision-2_en.pdf."},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Bazargani YT, de Boer A, Leufkens HG, Mantel-Teeuwisse AK. Selection of essential medicines for diabetes in low and middle income countries: a survey of 32 national essential medicines lists. PLoS One. 2014;9(9):e106072.","DOI":"10.1371\/journal.pone.0106072"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Budhram D, Benipal S, Bilimoria K, Maraj D, Wang R, Persaud N. Essential diabetes medicines and health outcomes in 127 countries. Diabetes Obes Metab. 2021;23(5):1121-1128.","DOI":"10.1111\/dom.14316"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Brhlikova P, Deivanayagam TA, Babar ZU, Osorio-de-Castro CGS, Caetano R, Pollock AM. Essential medicines concept and health technology assessment approaches to prioritising medicines: selection versus incorporation. J Pharm Policy Pract. 2023;16(1):88.","DOI":"10.1186\/s40545-023-00595-4"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Moulds, R. Guidelines and essential drug lists: of horses and carts. JPPR. 2010;40: 172-173.","DOI":"10.1002\/j.2055-2335.2010.tb00528.x"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Steiner L, Maraj D, Woods H, Jarvis J, Yaphe H, Adekoya I, et al. A comparison of national essential medicines lists in the Americas. Rev Panam Salud Publica. 2020;44:e5. Doi: 10.26633\/RPSP.2020.5.","DOI":"10.26633\/RPSP.2020.5"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann HJ, Reinap M, Piggott T, Laidm\u00e4e E, K\u00f6hler K, P\u014dld M, et al. The ecosystem of health decision making: from fragmentation to synergy. Lancet Public Health. 2022;7(4):e378-e390.","DOI":"10.1016\/S2468-2667(22)00057-3"},{"key":"ref35","unstructured":"Organizaci\u00f3n Panamericana de la Salud. Contribuci\u00f3n a la lista modelo desde la realidad de Am\u00e9rica Latina y el Caribe. En: Memoria de la Reuni\u00f3n Medicamentos Esenciales. 30 a\u00f1os contribuyendo a la Salud P\u00fablica. 2007:48-52. Disponible en: https:\/\/www.paho.org\/es\/file\/20799\/download?token=8G-yypHQ."},{"key":"ref36","unstructured":"Organizaci\u00f3n Panamericana de la Salud. PAHO\/WHO Collaborating Centre Spotlight Series. PAHO\/WHO CC on the Rational Use of Medicines. Centre for Pharmacology, School of Medicine, National University of La Plata. Disponible en: https:\/\/www.paho.org\/en\/pahowho-collaborating-centres\/spotlight-series-rational-use-medicine."}],"container-title":["Revista Panamericana de Salud P\u00fablica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/59271\/v48e32024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T17:22:50Z","timestamp":1707844970000},"score":1,"resource":{"primary":{"URL":"https:\/\/iris.paho.org\/handle\/10665.2\/59271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":36,"alternative-id":["RPSP.2024.3"],"URL":"https:\/\/doi.org\/10.26633\/rpsp.2024.3","relation":{},"ISSN":["1020-4989","1680-5348"],"issn-type":[{"value":"1020-4989","type":"print"},{"value":"1680-5348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]}}}